Details for: LATS1
Gene ID: 9113
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: LATS1
Ensembl ID: ENSG00000131023
Description: large tumor suppressor kinase 1
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 15.58rCSI 13.55%PRS 37.54
-
CSI 12.45rCSI 15.04%PRS 36.1
-
CSI 10.49rCSI 7.85%PRS 44.25
-
CSI 9.38rCSI 24.9%PRS 43.13
-
CSI 9.17rCSI 32.98%PRS 17.99
-
CSI 9.1rCSI 22.11%PRS 18.43
-
CSI 7.63rCSI 8.83%PRS 22.75
-
CSI 7.43rCSI 17.75%PRS 42.02
-
CSI 6.92rCSI 26.34%PRS 27.43
-
CSI 6.75rCSI 21.1%PRS 19.8
-
CSI 6.21rCSI 10%PRS 23.46
-
CSI 5.92rCSI 34.11%PRS 34.85
-
CSI 5.41rCSI 31.88%PRS 19.93
-
CSI 5.17rCSI 9.13%PRS 18.34
-
CSI 5.09rCSI 7.46%PRS 39.18
-
CSI 4.93rCSI 6.33%PRS 28.89
-
CSI 4.89rCSI 8%PRS 23.67
-
CSI 4.83rCSI 10.49%PRS 23.38
-
CSI 4.75rCSI 3.41%PRS 40.68
-
CSI 4.74rCSI 11.57%PRS 28.66
-
CSI 3.88rCSI 4.82%PRS 17.77
-
CSI 3.66rCSI 5.09%PRS 30.47
-
CSI 3.51rCSI 13.25%PRS 19.7
-
CSI 3.38rCSI 5.67%PRS 18.89
-
CSI 3.35rCSI 6.8%PRS 17.41
-
CSI 3.33rCSI 7.44%PRS 35.32
-
CSI 3.17rCSI 8.04%PRS 23.51
-
CSI 3.13rCSI 3.2%PRS 49.03
-
CSI 2.94rCSI 2.22%PRS 40.69
-
CSI 2.9rCSI 2.44%PRS 45.63
-
CSI 2.87rCSI 9.42%PRS 22.12
-
CSI 2.81rCSI 4.01%PRS 33
-
CSI 2.8rCSI 6.46%PRS 24.89
-
CSI 2.8rCSI 2.75%PRS 32.4
-
CSI 2.78rCSI 2.16%PRS 43.83
-
CSI 2.78rCSI 2.18%PRS 35.92
-
CSI 2.76rCSI 2.1%PRS 39.38
-
CSI 2.7rCSI 1.59%PRS 41.89
-
CSI 2.63rCSI 1.83%PRS 36.45
-
CSI 2.61rCSI 62.58%PRS 18.12
-
CSI 2.57rCSI 62.09%PRS 18.9
-
CSI 2.53rCSI 2.97%PRS 42.24
-
CSI 2.44rCSI 3.58%PRS 28.15
-
CSI 2.43rCSI 7.04%PRS 33.21
-
CSI 2.38rCSI 3.8%PRS 25.86
-
CSI 2.34rCSI 7.83%PRS 22.47
-
CSI 2.31rCSI 4.32%PRS 22.71
-
CSI 2.29rCSI 3.62%PRS 30.78
-
CSI 2.27rCSI 1.68%PRS 26.06
-
CSI 2.27rCSI 5.19%PRS 29.8
-
CSI 2.27rCSI 5.02%PRS 28.01
-
CSI 2.26rCSI 2.91%PRS 19.58
-
CSI 2.21rCSI 1.94%PRS 38.85
-
CSI 2.1rCSI 2.52%PRS 29.24
-
CSI 2.1rCSI 1.57%PRS 47.42
-
CSI 2.09rCSI 2.29%PRS 33.53
-
CSI 2.08rCSI 9.15%PRS 26.63
-
CSI 2.02rCSI 1.52%PRS 32.44
-
CSI 2.01rCSI 1.36%PRS 37.72
-
CSI 1.97rCSI 1.56%PRS 21.15
-
CSI 1.97rCSI 1.37%PRS 41.37
-
CSI 1.93rCSI 3.48%PRS 25.41
-
CSI 1.93rCSI 2.85%PRS 34.25
-
CSI 1.92rCSI 1.77%PRS 31.42
-
CSI 1.87rCSI 2%PRS 28.17
-
CSI 1.87rCSI 4.26%PRS 26.01
-
CSI 1.85rCSI 1.7%PRS 35.94
-
CSI 1.85rCSI 2.38%PRS 34.72
-
CSI 1.84rCSI 6.89%PRS 25.63
-
CSI 1.84rCSI 2.51%PRS 34
-
CSI 1.83rCSI 4.37%PRS 33.31
-
CSI 1.83rCSI 3.79%PRS 29.6
-
CSI 1.82rCSI 2.31%PRS 34.68
-
CSI 1.79rCSI 1.39%PRS 29.75
-
CSI 1.78rCSI 8.53%PRS 27.62
-
CSI 1.74rCSI 3.06%PRS 24.17
-
CSI 1.74rCSI 3.82%PRS 33.85
-
CSI 1.73rCSI 3.15%PRS 26.18
-
CSI 1.73rCSI 1.73%PRS 25.9
-
CSI 1.73rCSI 7.04%PRS 30.43
-
CSI 1.67rCSI 3.35%PRS 22.79
-
CSI 1.65rCSI 1.54%PRS 30.23
-
CSI 1.64rCSI 2.54%PRS 28.58
-
CSI 1.62rCSI 1.7%PRS 32.07
-
CSI 1.62rCSI 1.65%PRS 41.78
-
CSI 1.62rCSI 4.17%PRS 35.71
-
CSI 1.6rCSI 8.04%PRS 39.17
-
CSI 1.59rCSI 1.51%PRS 31.48
-
CSI 1.56rCSI 3.87%PRS 28.48
-
CSI 1.55rCSI 2.56%PRS 35
-
CSI 1.54rCSI 1.84%PRS 18.72
-
CSI 1.52rCSI 1.96%PRS 28.61
-
CSI 1.52rCSI 6.14%PRS 28.98
-
CSI 1.51rCSI 3.32%PRS 39.27
-
CSI 1.48rCSI 1.85%PRS 32.28
-
CSI 1.47rCSI 2.08%PRS 28.17
-
CSI 1.45rCSI 6.28%PRS 46.69
-
CSI 1.44rCSI 2.96%PRS 28.27
-
CSI 1.44rCSI 1.91%PRS 33.37
-
CSI 1.43rCSI 1.71%PRS 48.92
-
CSI 0.2rCSI 1.4%PRS 19.5%
-
CSI 0.3rCSI 5.3%PRS 26.9%
-
CSI 0.3rCSI 2.2%PRS 24.6%
-
CSI 0.4rCSI 0.5%PRS 28.0%
-
CSI 0.4rCSI 5.0%PRS 25.0%
-
CSI 0.4rCSI 8.7%PRS 25.6%
-
CSI 0.5rCSI 2.5%PRS 39.9%
-
CSI 0.6rCSI 1.7%PRS 24.2%
-
CSI 0.7rCSI 3.7%PRS 19.9%
-
CSI 0.7rCSI 2.9%PRS 29.2%
-
CSI 0.7rCSI 1.9%PRS 25.5%
-
CSI 0.7rCSI 1.5%PRS 21.9%
-
CSI 0.7rCSI 0.8%PRS 41.1%
-
CSI 0.8rCSI 2.1%PRS 28.3%
-
CSI 0.8rCSI 0.6%PRS 28.7%
-
CSI 0.8rCSI 0.7%PRS 27.7%
-
CSI 0.8rCSI 2.6%PRS 21.5%
-
CSI 0.9rCSI 2.0%PRS 37.1%
-
CSI 0.9rCSI 2.8%PRS 31.0%
-
CSI 0.9rCSI 1.3%PRS 31.2%
-
CSI 0.9rCSI 1.6%PRS 23.4%
-
CSI 0.9rCSI 1.8%PRS 38.2%
-
CSI 1.0rCSI 6.4%PRS 30.9%
-
CSI 1.0rCSI 3.9%PRS 46.6%
-
CSI 1.0rCSI 7.5%PRS 20.6%
-
CSI 1.0rCSI 3.0%PRS 65.4%
-
CSI 1.1rCSI 1.7%PRS 20.6%
-
CSI 1.1rCSI 3.0%PRS 34.5%
-
CSI 1.1rCSI 2.2%PRS 30.9%
-
CSI 1.1rCSI 3.6%PRS 27.0%
-
CSI 1.1rCSI 3.3%PRS 44.4%
-
CSI 1.2rCSI 9.6%PRS 28.0%
-
CSI 1.2rCSI 2.2%PRS 44.6%
-
CSI 1.2rCSI 1.7%PRS 24.0%
-
CSI 1.2rCSI 2.9%PRS 22.3%
-
CSI 1.2rCSI 2.1%PRS 29.5%
-
CSI 1.2rCSI 3.2%PRS 29.2%
-
CSI 1.2rCSI 1.9%PRS 35.8%
-
CSI 1.2rCSI 1.1%PRS 49.9%
-
CSI 1.3rCSI 3.3%PRS 27.9%
-
CSI 1.3rCSI 2.1%PRS 25.6%
-
CSI 1.3rCSI 1.8%PRS 29.2%
-
CSI 1.3rCSI 3.0%PRS 19.5%
-
CSI 1.3rCSI 2.0%PRS 34.3%
-
CSI 1.3rCSI 2.3%PRS 51.5%
-
CSI 1.4rCSI 1.7%PRS 26.9%
-
CSI 1.4rCSI 5.3%PRS 50.9%
-
CSI 1.4rCSI 2.0%PRS 32.3%
-
CSI 1.4rCSI 1.6%PRS 26.4%
-
CSI 1.4rCSI 1.1%PRS 30.5%
-
CSI 1.4rCSI 1.3%PRS 43.9%
-
CSI 1.4rCSI 2.2%PRS 30.6%
-
CSI 1.4rCSI 1.2%PRS 22.4%
-
CSI 1.4rCSI 2.8%PRS 31.3%
-
CSI 1.4rCSI 1.2%PRS 30.8%
-
CSI 1.4rCSI 1.7%PRS 48.9%
-
CSI 1.4rCSI 1.9%PRS 33.4%
-
CSI 1.4rCSI 3.0%PRS 28.3%
-
CSI 1.5rCSI 6.3%PRS 46.7%
-
CSI 1.5rCSI 2.1%PRS 28.2%
-
CSI 1.5rCSI 1.9%PRS 32.3%
-
CSI 1.5rCSI 3.3%PRS 39.3%
-
CSI 1.5rCSI 6.1%PRS 29.0%
-
CSI 1.5rCSI 2.0%PRS 28.6%
-
CSI 1.5rCSI 1.8%PRS 18.7%
-
CSI 1.6rCSI 2.6%PRS 35.0%
-
CSI 1.6rCSI 3.9%PRS 28.5%
-
CSI 1.6rCSI 1.5%PRS 31.5%
-
CSI 1.6rCSI 8.0%PRS 39.2%
-
CSI 1.6rCSI 4.2%PRS 35.7%
-
CSI 1.6rCSI 1.7%PRS 41.8%
-
CSI 1.6rCSI 1.7%PRS 32.1%
-
CSI 1.6rCSI 2.5%PRS 28.6%
-
CSI 1.7rCSI 1.5%PRS 30.2%
-
CSI 1.7rCSI 3.4%PRS 22.8%
-
CSI 1.7rCSI 7.0%PRS 30.4%
-
CSI 1.7rCSI 1.7%PRS 25.9%
-
CSI 1.7rCSI 3.2%PRS 26.2%
-
CSI 1.7rCSI 3.8%PRS 33.9%
-
CSI 1.7rCSI 3.1%PRS 24.2%
-
CSI 1.8rCSI 8.5%PRS 27.6%
-
CSI 1.8rCSI 1.4%PRS 29.8%
-
CSI 1.8rCSI 2.3%PRS 34.7%
-
CSI 1.8rCSI 3.8%PRS 29.6%
-
CSI 1.8rCSI 4.4%PRS 33.3%
-
CSI 1.8rCSI 2.5%PRS 34.0%
-
CSI 1.8rCSI 6.9%PRS 25.6%
-
CSI 1.9rCSI 2.4%PRS 34.7%
-
CSI 1.9rCSI 1.7%PRS 35.9%
-
CSI 1.9rCSI 4.3%PRS 26.0%
-
CSI 1.9rCSI 2.0%PRS 28.2%
-
CSI 1.9rCSI 1.8%PRS 31.4%
-
CSI 1.9rCSI 2.9%PRS 34.3%
-
CSI 1.9rCSI 3.5%PRS 25.4%
-
CSI 2.0rCSI 1.4%PRS 41.4%
-
CSI 2.0rCSI 1.6%PRS 21.2%
-
CSI 2.0rCSI 1.4%PRS 37.7%
-
CSI 2.0rCSI 1.5%PRS 32.4%
-
CSI 2.1rCSI 9.2%PRS 26.6%
-
CSI 2.1rCSI 2.3%PRS 33.5%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 713877307
Symbol: LATS1_HUMAN
Name: Serine/threonine-protein kinase LATS1
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 9988268
Title: Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity.
PubMed ID: 9988268
DOI: 10.1038/5960
PubMed ID: 10518011
Title: A human homolog of Drosophila warts tumor suppressor, h-warts, localized to mitotic apparatus and specifically phosphorylated during mitosis.
PubMed ID: 10518011
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 10831611
Title: Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor.
PubMed ID: 10831611
PubMed ID: 15144186
Title: Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.
PubMed ID: 15144186
DOI: 10.1021/ac035352d
PubMed ID: 15122335
Title: Tumor suppressor WARTS ensures genomic integrity by regulating both mitotic progression and G1 tetraploidy checkpoint function.
PubMed ID: 15122335
PubMed ID: 15220930
Title: LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1.
PubMed ID: 15220930
DOI: 10.1038/ncb1140
PubMed ID: 15688006
Title: The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1.
PubMed ID: 15688006
PubMed ID: 17525332
Title: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
PubMed ID: 17525332
PubMed ID: 18158288
Title: Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
PubMed ID: 18158288
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19369195
Title: Large-scale proteomics analysis of the human kinome.
PubMed ID: 19369195
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 20303269
Title: Ajuba LIM proteins are negative regulators of the Hippo signaling pathway.
PubMed ID: 20303269
PubMed ID: 19739119
Title: Molecular characterization of human homologs of yeast MOB1.
PubMed ID: 19739119
DOI: 10.1002/ijc.24878
PubMed ID: 19927127
Title: Regulation of ploidy and senescence by the AMPK-related kinase NUAK1.
PubMed ID: 19927127
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 24682284
Title: Evolutionary and Molecular Facts Link the WWC Protein Family to Hippo Signaling.
PubMed ID: 24682284
PubMed ID: 26437443
Title: MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
PubMed ID: 26437443
DOI: 10.1038/ncomms9357
PubMed ID: 28087714
Title: DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1/2.
PubMed ID: 28087714
PubMed ID: 28068668
Title: The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERalpha.
PubMed ID: 28068668
DOI: 10.1038/nature20829
PubMed ID: 28169360
Title: Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
PubMed ID: 28169360
DOI: 10.1038/srep42125
PubMed ID: 17344846
Title: Patterns of somatic mutation in human cancer genomes.
PubMed ID: 17344846
DOI: 10.1038/nature05610
Sequence Information:
- Length: 1130
- Mass: 126870
- Checksum: 11CFBCD8FD87DCD8
- Sequence:
MKRSEKPEGY RQMRPKTFPA SNYTVSSRQM LQEIRESLRN LSKPSDAAKA EHNMSKMSTE DPRQVRNPPK FGTHHKALQE IRNSLLPFAN ETNSSRSTSE VNPQMLQDLQ AAGFDEDMVI QALQKTNNRS IEAAIEFISK MSYQDPRREQ MAAAAARPIN ASMKPGNVQQ SVNRKQSWKG SKESLVPQRH GPPLGESVAY HSESPNSQTD VGRPLSGSGI SAFVQAHPSN GQRVNPPPPP QVRSVTPPPP PRGQTPPPRG TTPPPPSWEP NSQTKRYSGN MEYVISRISP VPPGAWQEGY PPPPLNTSPM NPPNQGQRGI SSVPVGRQPI IMQSSSKFNF PSGRPGMQNG TGQTDFMIHQ NVVPAGTVNR QPPPPYPLTA ANGQSPSALQ TGGSAAPSSY TNGSIPQSMM VPNRNSHNME LYNISVPGLQ TNWPQSSSAP AQSSPSSGHE IPTWQPNIPV RSNSFNNPLG NRASHSANSQ PSATTVTAIT PAPIQQPVKS MRVLKPELQT ALAPTHPSWI PQPIQTVQPS PFPEGTASNV TVMPPVAEAP NYQGPPPPYP KHLLHQNPSV PPYESISKPS KEDQPSLPKE DESEKSYENV DSGDKEKKQI TTSPITVRKN KKDEERRESR IQSYSPQAFK FFMEQHVENV LKSHQQRLHR KKQLENEMMR VGLSQDAQDQ MRKMLCQKES NYIRLKRAKM DKSMFVKIKT LGIGAFGEVC LARKVDTKAL YATKTLRKKD VLLRNQVAHV KAERDILAEA DNEWVVRLYY SFQDKDNLYF VMDYIPGGDM MSLLIRMGIF PESLARFYIA ELTCAVESVH KMGFIHRDIK PDNILIDRDG HIKLTDFGLC TGFRWTHDSK YYQSGDHPRQ DSMDFSNEWG DPSSCRCGDR LKPLERRAAR QHQRCLAHSL VGTPNYIAPE VLLRTGYTQL CDWWSVGVIL FEMLVGQPPF LAQTPLETQM KVINWQTSLH IPPQAKLSPE ASDLIIKLCR GPEDRLGKNG ADEIKAHPFF KTIDFSSDLR QQSASYIPKI THPTDTSNFD PVDPDKLWSD DNEEENVNDT LNGWYKNGKH PEHAFYEFTF RRFFDDNGYP YNYPKPIEYE YINSQGSEQQ SDEDDQNTGS EIKNRDLVYV